Misako Nagasaka
Overview
Explore the profile of Misako Nagasaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
2048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagasaka M, Roy U, Berk A, Liu G, Nadler E, Abrahami D
Future Oncol
. 2025 Mar;
:1-7.
PMID: 40084656
With the ongoing discovery of various oncogenic driver mutations in metastatic non-small cell lung cancer (mNSCLC), a precision medicine approach has emerged, characterized by targeted therapies for select patient populations....
2.
Hasan N, Yazdanpanah O, Harris J, Nagasaka M
Crit Rev Oncol Hematol
. 2025 Mar;
210:104676.
PMID: 40064250
Consolidative radiation is increasingly regarded as an effective treatment for oligometastatic and oligoprogressive non-small cell lung cancer (NSCLC). This systematic review examines the clinical evidence on the significance of consolidative...
3.
Ozaki A, Sayer M, Hamano H, Nagasaka M, Lee B, Doh J, et al.
Cardiooncology
. 2025 Mar;
11(1):26.
PMID: 40045435
Introduction: Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights. Methods: We performed...
4.
Arter Z, Shieh K, Nagasaka M, Ou S
Lung Cancer (Auckl)
. 2025 Feb;
16:1-9.
PMID: 39995769
Background: mutations are generally divided into three classes based on the different altered mechanism of activation. Methods: We queried the public AACR GENIE database (version 13.1), which includes tumor mutation...
5.
Hasan N, Nagasaka M
Expert Rev Respir Med
. 2025 Feb;
:1-10.
PMID: 39965618
Introduction: The first-line treatment landscape for patients with NSCLC harboring sensitizing mutations is rapidly evolving. Initially, osimertinib was the one and only option over earlier generation EGFR inhibitors based on...
6.
Arter Z, Lee A, Nagasaka M, Ou S
Cancer Med
. 2025 Feb;
14(4):e70665.
PMID: 39950716
Background: Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor-agnostic manner. However, the objective...
7.
Schram A, Goto K, Kim D, Macarulla T, Hollebecque A, OReilly E, et al.
N Engl J Med
. 2025 Feb;
392(6):566-576.
PMID: 39908431
Background: Neuregulin 1 () fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and...
8.
Brazel D, Smith J, Ou S, Nagasaka M
Target Oncol
. 2025 Feb;
PMID: 39903428
Targeted therapies have revolutionized treatment of non-small-cell lung cancer (NSCLC); however, epidermal growth factor receptor (EGFR) exon20ins mutations are resistant to tyrosine kinase inhibitors. Amivantamab utilizes multiple mechanisms of action...
9.
Arter Z, Ou S, Nagasaka M
J Thorac Oncol
. 2025 Jan;
20(1):12-16.
PMID: 39794098
No abstract available.
10.
Lee A, Nagasaka M
Lung Cancer (Auckl)
. 2024 Dec;
15:169-176.
PMID: 39717628
Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated...